Stocks · News reference

Agomab Says Phase 1 Data In 10 IPF Patients Show Favorable Safety, Target Engagement For Inhaled AGMB-447; Submits CTA For 120-Patient Phase 2 INSPIRIA Study, Targets Start In H2 2026

Sep 14, 2026, 8:08 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 25, 2026, 4:27 PMBenzinga Newsdesk
AgomAb Therapeutics shares are trading higher after Piper Sandler initiated coverage on the stock with an Overweight rating and announced a $60 price target.
AGMB
BenzingaAug 25, 2026, 12:10 PMAvi Kapoor
This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Analysts change outlook on top names. See all rating changes, including upgrades/downgrades/initiations. Coverage initiated on various stocks.
AGMB APMD JBTM JMKE KDK
BenzingaAug 25, 2026, 9:40 AMBenzinga Newsdesk
Piper Sandler Initiates Coverage On AgomAb Therapeutics with Overweight Rating, Announces Price Target of $60
Piper Sandler analyst Yasmeen Rahimi initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Overweight rating and announces Price Target of $60.
AGMB